{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T11:06:16Z","timestamp":1789815976822,"version":"4.0.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":3380,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1093\/annonc\/mdq032","type":"journal-article","created":{"date-parts":[[2010,2,12]],"date-time":"2010-02-12T04:04:03Z","timestamp":1265947443000},"page":"1779-1785","source":"Crossref","is-referenced-by-count":52,"title":["A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy"],"prefix":"10.1016","volume":"21","author":[{"given":"D.","family":"Kanagavel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.A.","family":"Pokataev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.Y.","family":"Fedyanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.A.","family":"Tryakin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.S.","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.N.","family":"Narimanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.S.","family":"Yakovleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Tjulandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdq032_bb0010","series-title":"GLOBOCAN 2002 Cancer Incidence, Mortality and Prevalence Worldwide. IARC Cancerbase No. 5, Version 2.0","author":"Ferlay","year":"2004"},{"key":"10.1093\/annonc\/mdq032_bb0015","first-page":"55","article-title":"Gastric cancer","volume":"19\u201320","author":"Correa","year":"1994","journal-title":"Cancer Surv"},{"key":"10.1093\/annonc\/mdq032_bb0020","series-title":"The World Health Report 2003","author":"World Health Organization","year":"2003"},{"key":"10.1093\/annonc\/mdq032_bb0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0895-4356(02)00534-6","article-title":"Gastric cancer epidemiology and risk factors","volume":"56","author":"Kelley","year":"2003","journal-title":"J Clin Epidemiol"},{"key":"10.1093\/annonc\/mdq032_bb0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.critrevonc.2009.01.004","article-title":"Gastric cancer","volume":"71\u201372","author":"Catalano","year":"2009","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1093\/annonc\/mdq032_bb0035","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S1470-2045(07)70245-0","article-title":"Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995\u201399: results of the EUROCARE-4 study","volume":"8","author":"Berrino","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0040","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0045","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2006.08.0135","article-title":"Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research","volume":"25","author":"Roth","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0050","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdq032_bb0055","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.clon.2004.10.006","article-title":"Review of second-line chemotherapy for advanced gastric adenocarcinoma","volume":"17","author":"Wilson","year":"2005","journal-title":"Clin Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0060","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1023\/A:1008373814453","article-title":"A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer","volume":"11","author":"Graziano","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0065","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1159\/000227393","article-title":"Continuous 5-fluorouracil and leucovorin as a second-line therapy for advanced gastric carcinoma","volume":"51","author":"Schmitz","year":"1994","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdq032_bb0070","first-page":"1305","article-title":"Bolus and infusional 5-fluorouracil combined with cisplatin in advanced gastric cancer","volume":"7","author":"Barone","year":"2000","journal-title":"Oncol Rep"},{"key":"10.1093\/annonc\/mdq032_bb0075","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/oxfordjournals.annonc.a059017","article-title":"Weekly high dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer","volume":"5","author":"Vanhoeffer","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0080","first-page":"89","article-title":"Paclitaxel and carboplatin in pre-treated advanced gastric cancer: a phase II study","volume":"9","author":"Stathopoulos","year":"2002","journal-title":"Oncol Rep"},{"key":"10.1093\/annonc\/mdq032_bb0085","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/oxfordjournals.jjco.a039440","article-title":"An early phase II study of 5-fluorouracil combined with cisplatinum as a second-line chemotherapy against metastatic gastric cancer","volume":"21","author":"Ohtsu","year":"1991","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0090","unstructured":"Chau I, Norman AR, Ross PJ. Multivariate prognostic factor analysis and second-line treatment in locally advanced and metastatic oesophago-gastric cancer\u2014pooled analysis of 1080 patients from three multicentre randomised controlled trials using individual patient data. Proceedings of the ASCO Gastrointestinal Cancers Symposium, San Francisco, California (Abstr 5). 2004."},{"key":"10.1093\/annonc\/mdq032_bb0095","first-page":"2667","article-title":"A phase II study of weekly paclitaxel as second-line chemotherapy for advanced gastric cancer (CCOG0302 study)","volume":"27","author":"Kodera","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1093\/annonc\/mdq032_bb0100","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1097\/00001813-199909000-00006","article-title":"Mitomycin C continuous infusion as salvage chemotherapy in pre-treated patients with advanced gastric cancer","volume":"10","author":"Hartmann","year":"1999","journal-title":"Anticancer Drugs"},{"issue":"Suppl","key":"10.1093\/annonc\/mdq032_bb0105","first-page":"15s","article-title":"Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"27","author":"Thuss-Patience","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0110","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2004.08.154","article-title":"Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer\u2014pooled analysis from three multicenter, randomized, controlled trials using individual patient data","volume":"22","author":"Chau","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0115","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/jjco\/hyh120","article-title":"Long-term survival and prognostic factors in patients with metastatic gastric cancers treated with chemotherapy in the Japan Clinical Oncology Group (JCOG) study","volume":"34","author":"Yoshida","year":"2004","journal-title":"Jpn J Clin Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0120","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1093\/annonc\/mdl501","article-title":"Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma","volume":"18","author":"Lee","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdq032_bb0125","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/sj.bjc.6604732","article-title":"Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?","volume":"99","author":"Catalano","year":"2008","journal-title":"Br J Can"},{"key":"10.1093\/annonc\/mdq032_bb0130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1471-2407-9-110","article-title":"A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer","volume":"9","author":"Ji","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1093\/annonc\/mdq032_bb0135","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00280-005-0027-2","article-title":"Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer","volume":"57","author":"Park","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdq032_bb0140","first-page":"499","article-title":"Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy","volume":"28","author":"Stahl","year":"2005","journal-title":"Onkologie"},{"key":"10.1093\/annonc\/mdq032_bb0145","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0959-8049(97)10090-9","article-title":"Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?","volume":"34","author":"Andreyev","year":"1998","journal-title":"Eur J Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419400562?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419400562?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/21\/9\/1779\/339558\/mdq032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:37:50Z","timestamp":1624700270000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419400562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0923753419400562"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdq032","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]}}}